Compare WKHS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | RVPH |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 71.0M |
| IPO Year | N/A | N/A |
| Metric | WKHS | RVPH |
|---|---|---|
| Price | $0.78 | $0.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.75 | ★ $3.33 |
| AVG Volume (30 Days) | ★ 4.1M | 3.8M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,620,296.00 | N/A |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $0.53 | $0.25 |
| 52 Week High | $15.75 | $4.28 |
| Indicator | WKHS | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 57.09 |
| Support Level | $0.79 | $0.55 |
| Resistance Level | $0.90 | $0.63 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 45.67 | 79.42 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.